A comprehensive evaluation of the Ewing sarcoma surface and global proteomes reveals actionable immunotherapeutic targets.

ABSTRACT: Ewing sarcoma (EwS) is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. While the survival rate of patients diagnosed with localized disease is ~70%, this decreases to ~30% for patients with metastatic disease and only ~10% for treatment refractory disease, which remain unchanged for decades. Clearly, new therapeutic strategies are urgently needed for metastatic/refractory EwS. In this study, 19 unique EwS patient or cell line-derived xenografts were analyzed using proteomics to identify surface proteins with potential for immunotherapeutic targeting. Plasma membranes were enriched from each model via density gradient ultracentrifugation and compared to a reference standard consisting of 12 immortalized non-EwS cell lines prepared in a similar manner. In parallel, global proteome analysis was carried out on each model and reference controls to compliment the surfaceome data. All models were analyzed by Tandem Mass Tags (TMT)-based mass spectrometry to quantify identified proteins.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Ewing's Sarcoma Cell

SUBMITTER: Gian Luca Negri  

LAB HEAD: Gregg Morin

PROVIDER: PXD043375 | Pride | 2023-09-29

REPOSITORIES: Pride